Insider · CIK 0001383292
Charles A Rowland Jr
Files at VKTX (Viking Therapeutics, Inc.), GBIO (Generation Bio Co.). First filing Dec 5, 2023, latest Oct 28, 2025.
In brief
Charles A Rowland Jr files SEC Form 4 as director at VKTX (Viking Therapeutics, Inc.), and also at GBIO (Generation Bio Co.). Since Dec 5, 2023, Charles A Rowland Jr has reported 1 open-market buy worth $478k and 1 open-market sell worth $2.1M, the latest filed on Oct 28, 2025.
A track record needs three past buys with six months of prices behind them; Charles A Rowland Jr has 0, so none is measured yet.
The newest scored trade: sold $2.1M of VKTX on Oct 27, 2025, filed Oct 28, 2025, scored 60 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $2.1M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VKTX: Viking Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Viking Therapeutics, Inc. | $2.1M 60,000 shares | -67% | +80% from low-52% from high | |
| 58Moderate | Generation Bio Co. | $478k 342,960 shares | +179% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 27, 2025 | VKTX VIKING THERAPEUTICS, INC. | 60,000 0.05% of outstanding | $2.1M | Oct 27, 2025 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | GBIO Generation Bio Co. | UTender of shares Common Stock | -53,475 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -3,000 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -4,246 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -5,200 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -1,500 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -1,920 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -2,500 | - | - | 0 | Feb 9, 2026 |
| Feb 9, 2026 | GBIO Generation Bio Co. | DDisposition to issuer Stock Option (right to buy)derivative | -6,000 | - | - | 0 | Feb 9, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +3,150 | $0.00 | $0 | 33,150 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Jan 5, 2026 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +16,000 | $4.48 | $72k | 46,000 | Oct 28, 2025 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +22,000 | $5.80 | $128k | 68,000 | Oct 28, 2025 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +22,000 | $4.88 | $107k | 90,000 | Oct 28, 2025 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -60,000 | $35.57 | $2.1M | 30,000 | Oct 28, 2025 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -16,000 | $0.00 | $0 | 0 | Oct 28, 2025 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -22,000 | $0.00 | $0 | 0 | Oct 28, 2025 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -22,000 | $0.00 | $0 | 0 | Oct 28, 2025 |
| Jun 4, 2025 | GBIO Generation Bio Co. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 6, 2025 |
| Dec 1, 2023 | GBIO Generation Bio Co. | POpen-market purchase Common Stock | +192,960 | $1.31 | $253k | 384,757 | Dec 5, 2023 |
| Dec 4, 2023 | GBIO Generation Bio Co. | POpen-market purchase Common Stock | +150,000 | $1.50 | $225k | 534,757 | Dec 5, 2023 |
Questions about Charles A Rowland Jr
Answered from the filings on this page, as of the latest one.
Is Charles A Rowland Jr buying or selling?
In the last 12 months Charles A Rowland Jr reported 0 open-market buys worth $0 and 1 open-market sell worth $2.1M on SEC Form 4; the latest was sold $2.1M of VKTX on Oct 27, 2025. Grants, option exercises and tax withholding are not counted.
How did Charles A Rowland Jr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles A Rowland Jr has 0.
Where does Charles A Rowland Jr file Form 4?
Charles A Rowland Jr has filed Form 4 at VKTX (Viking Therapeutics, Inc.); GBIO (Generation Bio Co.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.